A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study.
A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study.
复制标题
醋酸亮丙瑞林治疗晚期上皮性卵巢癌患者的 II 期试验。
DOI：
10.1097/00000421-199204000-00006
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
Barrett,RJ
中科院分区：
文献类型：
--
作者：
Miller,DS;Brady,MF;Barrett,RJ
25例可评价的晚期或复发性上皮性卵巢癌患者（手术、放疗和/或化疗不再可控）接受醋酸亮丙瑞林（一种促性腺激素释放激素激动剂）治疗，每日1 mg皮下注射。在25例患者中观察到1例部分缓解（4%）。响应率的95%置信上限为17.6%。15名患者（60%）表现出至少8周的稳定疾病，9名患者（36%）在接受治疗时发生进展性癌症。该方案耐受性良好，无患者发生危及生命的毒性。轻度毒性包括2例患者（8%）的白细胞减少症、2例患者（8%）的血小板减少症、5例患者（20%）的胃肠道毒性、4例患者（16%）的贫血、1例患者（4%）的潮热和1例患者（4%）的面部肿胀。因此，醋酸亮丙瑞林耐受性良好，但在治疗化疗难治性卵巢腺癌患者中的活性不显著。
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily. One partial response (4%) was observed among the 25 patients. The upper 95% confidence bound of the response rate is 17.6%. Fifteen patients (60%) exhibited stable disease for at least 8 weeks, and 9 patients (36%) developed progressive cancer while receiving treatment. The regimen was well tolerated with no patient experiencing life-threatening toxicity. Mild toxicities included leukopenia in 2 patients (8%), thrombocytopenia in 2 patients (8%), gastrointestinal toxicity in 5 patients (20%), anemia in 4 patients (16%), hot flashes in 1 patient (4%), and facial swelling in 1 patient (4%). Thus, leuprolide acetate was well tolerated but has insignificant activity in treating patients with chemotherapy-refractory ovarian adenocarcinoma.